Poleon Shervonne, Twa Michael, Schoenberger-Godwin Yu-Mei, Fifolt Mathew, Racette Lyne
Department of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Ophthalmol Sci. 2025 Jan 13;5(4):100706. doi: 10.1016/j.xops.2025.100706. eCollection 2025 Jul-Aug.
To use group-based trajectory modeling to identify patterns of medication adherence in patients with primary open-angle glaucoma (POAG) and to identify factors associated with each pattern.
Prospective cohort study.
Seventy-two patients with POAG who were enrolled in a National Institutes of Health-funded progression study at the University of Alabama at Birmingham were included in this study. Patients were required to be >18 years of age, have a diagnosis of POAG, and be prescribed hypotensive eye drops to treat their glaucoma.
Fifty-two weeks of mean weekly medication adherence data were collected using Medication Event Monitoring Systems. Group-based trajectory modeling was used to estimate models with 2, 3, 4, 5, and 6 medication adherence trajectory groups. Self-reported race and illness perception were included as covariates. The model with the lowest Bayesian information criterion (which provides a measure of the trade-off between model fit and model complexity) and the highest number of clinically relevant trajectory groups was deemed optimal.
Medication adherence trajectory groups.
The Bayesian information criterion was -1041.1 for the 2-group model, -755.9 for the 3-group model, -643.8 for the 4-group model, -590.4 for the 5-group model, and -559.0 for the 6-group model. We identified the 4-group model as the most optimal. The 4 trajectory groups estimated by this model were near-perfect adherence (51.8% of participants), good adherence (23.2% of participants), declining adherence (18.1% of participants), and poor adherence (6.9% of participants). Compared with the poor adherence group, a higher illness perception score predicted a lower probability of membership in the good (B = -0.276, = 0.042) and declining (B = -0.303, = 0.028) adherence groups.
Medication adherence is an important clinical outcome that is associated with disease severity and disease progression in POAG. Further investigation of this important topic may reveal other shared clinical characteristics that can be used to identify patients who may be at risk for adverse clinical outcomes such as glaucoma progression.
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
运用基于群组的轨迹模型来识别原发性开角型青光眼(POAG)患者的药物依从性模式,并确定与每种模式相关的因素。
前瞻性队列研究。
本研究纳入了72例POAG患者,他们参与了美国国立卫生研究院资助的、在阿拉巴马大学伯明翰分校进行的一项进展研究。患者需年满18岁,被诊断为POAG,并被开具降眼压眼药水来治疗青光眼。
使用药物事件监测系统收集52周的平均每周药物依从性数据。运用基于群组的轨迹模型来估计包含2、3、4、5和6个药物依从性轨迹组的模型。自我报告的种族和疾病认知作为协变量纳入。具有最低贝叶斯信息准则(它衡量了模型拟合度与模型复杂性之间的权衡)且临床相关轨迹组数量最多的模型被视为最优模型。
药物依从性轨迹组。
2组模型的贝叶斯信息准则为-1041.1,3组模型为-755.9,4组模型为-643.8,5组模型为-590.4,6组模型为-559.0。我们确定4组模型为最优模型。该模型估计的4个轨迹组分别为近乎完美依从(51.8%的参与者)、良好依从(23.2%的参与者)、依从性下降(18.1%的参与者)和依从性差(6.9%的参与者)。与依从性差的组相比,更高的疾病认知得分预示着属于良好依从组(B = -0.276,P = 0.042)和依从性下降组(B = -0.303,P = 0.028)的概率更低。
药物依从性是一项重要的临床结果,与POAG的疾病严重程度和疾病进展相关。对这一重要主题的进一步研究可能会揭示其他共同的临床特征,这些特征可用于识别可能面临青光眼进展等不良临床结局风险的患者。
在本文末尾的脚注和披露中可能会找到专有或商业披露信息。